MRUS - Merus NV (Healthcare: Biotechnology) Projected Earnings Date: 2024-08-05    (Delayed quote data   2025-01-03)
Last
 43.16		 Change
 ⇑ +0.86   (+2.03%)		 Volume
  538,430
Open
 42.46		 High
 43.45		 Low
 42.46
8EMA (Daily)
 42.53		 40EMA (Daily)
 44.89		 50EMA (Daily)
 45.58		 STO (Daily)
 29.440		 MACD Hist (Daily)
 0.433
8EMA (Weekly)
 44.448		 40EMA (Weekly)
 46.47		 50EMA (Weekly)
 45.25		 STO (Weekly)
 11.655		 MACD Hist (Weekly)
 -2.325
Company Profile
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com